Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 87Breast Neoplasms 49Prostatic Neoplasms 42Squamous Cell Carcinoma of Head and Neck 34Lung Neoplasms 24Neoplasms 19Stomach Neoplasms 18Head and Neck Neoplasms 17Neoplasm Metastasis 16Parkinson Disease 4, Autosomal Dominant Lewy Body 14Urinary Bladder Neoplasms 13Carcinoma, Transitional Cell 11Triple Negative Breast Neoplasms 10Ovarian Neoplasms 8Endometrial Neoplasms 8Carcinoma, Squamous Cell 8Adenocarcinoma 8HER2-positive Breast Cancer 7Non-Muscle Invasive Bladder Neoplasms 6Melanoma 6Carcinoma 6Small Cell Lung Carcinoma 5Prostatic Neoplasms, Castration-Resistant 5Nasopharyngeal Carcinoma 5Esophageal Neoplasms 5Uterine Cervical Neoplasms 4Sarcoma 4Oropharyngeal Neoplasms 4Fallopian Tube Neoplasms 4Esophageal Squamous Cell Carcinoma 4

Interventions

Specimen Handling 8pembrolizumab 7enfortumab vedotin 7Magnetic Resonance Spectroscopy 6avelumab 4Nivolumab 4Gemcitabine 3cabozantinib 2Ipilimumab 2Immunoglobulin G 2Disulfides 2Cisplatin 2Carboplatin 2CTLA-4 Antigen 2Biopsy 2vinflunine 1tremelimumab 1tocilizumab 1tamibarotene 1relatlimab 1eribulin 1erdafitinib 1durvalumab 1copanlisib 1atezolizumab 1Watchful Waiting 1Standard of Care 1Propranolol 1Practice Guidelines as Topic 1Plasmapheresis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ureteral Neoplasms × Docetaxel × 1 year × Clear all
NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Astellas Pharma Inc

Phase 3 Completed
608 enrolled 22 charts 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡